{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.67","upperLimit":"41.51","value":"16.78"},{"groupId":"OG001","lowerLimit":"0","upperLimit":"0","value":"0"},{"groupId":"OG002","lowerLimit":"2.48","upperLimit":"38.78","value":"15.39"},{"groupId":"OG003","lowerLimit":"5.58","upperLimit":"47.46","value":"23.08"},{"groupId":"OG004","lowerLimit":"5.89","upperLimit":"41.42","value":"20.6"},{"groupId":"OG005","lowerLimit":"7.64","upperLimit":"39.35","value":"21.25"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"13"},{"groupId":"OG004","value":"23"},{"groupId":"OG005","value":"29"}],"units":"Participants"}],"description":"Percent of patients not yet progressed at 1 year as estimated by the Kaplan-Meier method. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECISTv1.1), as a \\>=20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. Clinical progression was also counted as an event for this analysis.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive cabozantinib-s-malate (XL184), 40mg/m2/day orally (PO) on a continuous dosing schedule using a dosing nomogram on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Ewing's Sarcoma"},{"description":"Patients receive cabozantinib-s-malate (XL184), 40mg/m2/day orally (PO) on a continuous dosing schedule using a dosing nomogram on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG001","title":"Rhabdomyosarcoma"},{"description":"Patients receive cabozantinib-s-malate (XL184), 40mg/m2/day orally (PO) on a continuous dosing schedule using a dosing nomogram on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG002","title":"Non-Rhabdomyosarcoma Soft Tissue Sarcoma"},{"description":"Patients receive cabozantinib-s-malate (XL184), 40mg/m2/day orally (PO) on a continuous dosing schedule using a dosing nomogram on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG003","title":"Wilms Tumor"},{"description":"Patients receive cabozantinib-s-malate (XL184), 40mg/m2/day orally (PO) on a continuous dosing schedule using a dosing nomogram on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG004","title":"Rare Tumors"},{"description":"Patients receive cabozantinib-s-malate (XL184), 40mg/m2/day orally (PO) on a continuous dosing schedule using a dosing nomogram on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG005","title":"Osteosarcoma"}],"paramType":"NUMBER","populationDescription":"All patients who met the evaluable for response criteria outlined in section 9.4 of the ADVL1622 protocol.","reportingStatus":"POSTED","timeFrame":"Up to 1 year","title":"Time to Progression (TTP)","type":"SECONDARY","unitOfMeasure":"Percentage of patients"}